Literature DB >> 20158441

Development and validation of a transcreener assay for detection of AMP- and GMP-producing enzymes.

Matt Staeben1, Karen M Kleman-Leyer, Andrew L Kopp, Thane A Westermeyer, Robert G Lowery.   

Abstract

Screening of AMP- and GMP-producing enzymes such as phosphodiesterases (PDEs), ligases, and synthetases would be simplified by the ability to directly detect unmodified nucleoside monophosphates. To address this need, we developed polyclonal and monoclonal antibodies that recognize AMP and GMP with nanomolar sensitivity and high selectivity vs. the corresponding triphosphate and 3',5'-cyclic monophosphate nucleotides that serve as substrates for many enzymes in these classes. One of these antibodies was used to develop a Transcreener AMP/GMP assay with a far red fluorescence polarization (FP) readout. This polyclonal antibody exhibited extremely high selectivity, with IC(50) ratios of 6,000 for ATP/AMP, 3,810 for cAMP/AMP, and 6,970 for cGMP/GMP. Standard curves mimicking enzymatic conversion of cAMP, cGMP, and ATP to the corresponding monophosphates yielded Z' values of >0.85 at 10% conversion. The assay reagents were shown to be stable for 24 h at room temperature, both before and after dispensing. The Transcreener AMP/GMP FP assay was used for enzymatic detection of cGMP- and cAMP-dependent PDEs 4A1A, 3A, and 9A2 and ATP-dependent ligases, acetyl CoA synthetase, and ubiquitin- activating enzyme (UBE1). Shifts of >100 mP were observed in the linear part of the progress curves for all enzymes tested, and the PDE isoforms exhibited the expected substrate and inhibitor selectivity. These studies demonstrate that direct immunodetection of AMP and GMP is a flexible, robust enzyme assay method for diverse AMP- and GMP-producing enzymes. Moreover, it eliminates many of the shortcomings of other methods including the need for fluorescently labeled substrates, the low signal:background inherent in substrate depletion assays, and the potential for interference with coupling enzymes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20158441      PMCID: PMC2894640          DOI: 10.1089/adt.2009.0254

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  30 in total

1.  Overcoming compound interference in fluorescence polarization-based kinase assays using far-red tracers.

Authors:  Kevin L Vedvik; Hildegard C Eliason; Randy L Hoffman; Jasmin R Gibson; Kevin R Kupcho; Richard L Somberg; Kurt W Vogel
Journal:  Assay Drug Dev Technol       Date:  2004-04       Impact factor: 1.738

Review 2.  The purinome, a complex mix of drug and toxicity targets.

Authors:  Timothy A J Haystead
Journal:  Curr Top Med Chem       Date:  2006       Impact factor: 3.295

Review 3.  Phosphodiesterases in the CNS: targets for drug development.

Authors:  Frank S Menniti; W Stephen Faraci; Christopher J Schmidt
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

4.  Evaluating the utility of the HTRF Transcreener ADP assay technology: a comparison with the standard HTRF assay technology.

Authors:  Lin Hong; Christopher M Quinn; Yong Jia
Journal:  Anal Biochem       Date:  2009-05-03       Impact factor: 3.365

Review 5.  Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.

Authors:  T J Torphy; B J Undem
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

Review 6.  Zardaverine: a cyclic AMP specific PDE III/IV inhibitor.

Authors:  C Schudt; S Winder; M Eltze; U Kilian; R Beume
Journal:  Agents Actions Suppl       Date:  1991

Review 7.  Acetyl-coenzyme A synthetase (AMP forming).

Authors:  V J Starai; J C Escalante-Semerena
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

8.  Screening of natural products extracts for the presence of phosphodiesterase inhibitors using liquid chromatography coupled online to parallel biochemical detection and chemical characterization.

Authors:  T Schenk; G J Breel; P Koevoets; S van den Berg; A C Hogenboom; H Irth; U R Tjaden; J van der Greef
Journal:  J Biomol Screen       Date:  2003-08

9.  A fluorescence polarization assay for cyclic nucleotide phosphodiesterases.

Authors:  Wei Huang; Yan Zhang; J Richard Sportsman
Journal:  J Biomol Screen       Date:  2002-06

Review 10.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.

Authors:  Hossein A Ghofrani; Ian H Osterloh; Friedrich Grimminger
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

View more
  6 in total

1.  Development and validation of a generic fluorescent methyltransferase activity assay based on the transcreener AMP/GMP assay.

Authors:  Tony A Klink; Matt Staeben; Kim Twesten; Andrew L Kopp; Meera Kumar; Rebecca Schall Dunn; Cori A Pinchard; Karen M Kleman-Leyer; Martin Klumpp; Robert G Lowery
Journal:  J Biomol Screen       Date:  2011-09-28

2.  A pathophysiological role of PDE3 in allergic airway inflammation.

Authors:  Jan Beute; Melanie Lukkes; Ewout P Koekoek; Hedwika Nastiti; Keerthana Ganesh; Marjolein Jw de Bruijn; Steve Hockman; Menno van Nimwegen; Gert-Jan Braunstahl; Louis Boon; Bart N Lambrecht; Vince C Manganiello; Rudi W Hendriks; Alex KleinJan
Journal:  JCI Insight       Date:  2018-01-25

3.  Fluorescence polarization assays in small molecule screening.

Authors:  Wendy A Lea; Anton Simeonov
Journal:  Expert Opin Drug Discov       Date:  2011-01       Impact factor: 6.098

4.  Development of a Rapid Mass Spectrometric Determination of AMP and Cyclic AMP for PDE3 Activity Study: Application and Computational Analysis for Evaluating the Effect of a Novel 2-oxo-1,2-dihydropyridine-3-carbonitrile Derivative as PDE-3 Inhibitor.

Authors:  Ilaria Cicalini; Barbara De Filippis; Nicola Gambacorta; Antonio Di Michele; Silvia Valentinuzzi; Alessandra Ammazzalorso; Alice Della Valle; Rosa Amoroso; Orazio Nicolotti; Piero Del Boccio; Letizia Giampietro
Journal:  Molecules       Date:  2020-04-15       Impact factor: 4.411

5.  Homogeneous single-label cGMP detection platform for the functional study of nitric oxide-sensitive (soluble) guanylyl cyclases and cGMP-specific phosphodiesterases.

Authors:  Kari Kopra; Iraida Sharina; Emil Martin; Harri Härmä
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

6.  First-in-Class Inhibitors of Sulfur Metabolism with Bactericidal Activity against Non-Replicating M. tuberculosis.

Authors:  Prakash B Palde; Ashima Bhaskar; Laura E Pedró Rosa; Franck Madoux; Peter Chase; Vinayak Gupta; Timothy Spicer; Louis Scampavia; Amit Singh; Kate S Carroll
Journal:  ACS Chem Biol       Date:  2015-11-11       Impact factor: 5.100

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.